Yes.
Now, check this out for a bloody show stopper.
With the full stated adoption, the Breast cancer market in the US alone is worth AUD $5.5b in peak sales at 80% penetration.
That's $16.5B at 3x peak revenue or $80 per share.
Bisantrene reprograms M2b macrophages to m1, which promotes anti-cancer effects.
Paclitaxel also reprograms M2 macrophages to M1, which promote anti-cancer effects.
Combining Doxorubicin with Paclitaxel in advanced breast cancer drives an 83% ORR, however 50% had LVEF abnormalities and 20% developed congestive heart failure. This combination is extremely effective but impossible to use in patients due to cardiotoxicity.
Bisantrene reprograms the tumor microenvironment similar to Paclitaxel. Thus, Bisantrene in combination with Doxorubicin achieving 83% ORR with a significant reduction in cardiac events is very much a possibility from the P2 umbrella trial.
Yes. Now, check this out for a bloody show stopper.With the full...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.020(1.20%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $177.8K | 108.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |